Expert Scientific Advisory Committee (ESAC)

MMV’s Expert Scientific Advisory Committee (ESAC) helps to identify the best projects worthy of inclusion in the portfolio and continues to monitor progress through an annual review of all projects. This committee consists of experts from both industry and academia and covers the full range of expertise required to assess projects that are engaging in the extremely complex process of drug research and development.

ESAC Members

Dr Tesfaye Biftu Distinguished professor, National institute of pharmaceutical sciences, ASTU, Adama, Ethiopia

Dr Nick Cammack Former Senior Vice-President and Head, Medicines Development Campus for Diseases of the Developing World at GSK, Tres Cantos, Spain

Sir Simon Campbell Former SVP for WW Discovery, Pfizer, organic chemist, UK

Robert Clay Consultant/Managing Director, Highbury Regulatory Science Limited; and Board Member (President 2017) at TOPRA, UK

Dr Anne Cooper Programme Director, Sosei Heptares, UK

Prof Brian Cox Professor of Pharmaceutical Chemistry, University of Sussex, School of Life Sciences, UK

Ms Delese Mimi Darko Chief Executive Officer, Safety Monitoring & Clinical Trials Division, Food and Drugs Authority, Ghana

Dr Monica Hemben Eimunjeze Director, Registration & Regulatory Affairs Directorate, National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria

Dr Rick Fairhurst, Pharmacovigilance Medical Director, Chief Medical Office, Oncology R&D, AstraZeneca

Dr Tim Hammond Independent Pharmaceutical Preclinical Safety Consultant at Preclinical Safety Consulting Ltd, UK

Dr Laurent Hennequin Research Director, Galderma R&D, La Tour de Peilz, Switzerland

Dr Marcus Lacerda Public Health Specialist, Fiocruz, Brazil 

Dr John Pottage Former Chief Scientific and Medical Officer, ViiV Healthcare; and Co-Chairman MMV ESAC (Development), USA  

Dr Robert Riley Executive Vice President, Drug Discovery, Evotec, UK

Dr Esperança Sevene Senior Research Fellow, Manhiça Health Research Centre, Mozambique

Prof Dennis Shanks Director, Australian Defence Force Malaria and Infectious Disease Institute, Australia

Dr Peter Siegl, Siegl Pharma Consulting, USA

Dr Shailja Singh, Associate Professor, Special Centre for Molecular Medicine, Jawaharlal Nehru University, India

Prof Dennis Smith Former Vice President, PGRD, Pfizer, Kent, UK

Dr Jane Stewart Reproductive Toxicology Associate, ApconiX, UK

Dr John R.J. Surtees Managing Partner, Berzelius Integrated Solutions, Belgium

Dr Melissa Tassinari, PhD DABT Former Senior Clinical Advisor, Food and Drug Administration, USA

Prof Stephen Ward Deputy Director, Liverpool School of Tropical Medicine, UK

Dr Michael Witty Drug Discovery Consultant and former Vice-President Pfizer R&D; Co-Chairman MMV ESAC (Discovery), UK

Dr Dyann Wirth Director, Harvard Malaria Initiative, Harvard School of Public Health, USA

Dr Taiyin Yang Executive Vice President, Pharmaceutical Development and Manufacturing, Gilead Sciences, USA

Dr Takeshi Yura Vice President Medicinal Chemistry, Jubilant Biosys Ltd, India

Dr Robert T. Jacobs  Drug Discovery Consultant and former Vice-President of Chemistry, Anacor Pharmaceuticals, USA

Dr Dominique Soldati Favre, Professor and Head of Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Switzerland

Dr Phil Rosenthal, Professor, Department of Medicine, University of California, San Francisco, USA

Dr Lynn Marks, former Senior Vice President GlaxoSmithKline R&D

Dr. Pol Vandenbrouke, Chief Medical Officer, Hospital Business Unit, Pfizer Inc.

George Mooney, Drug Discovery Consultant and former Vice-President of Pfizer Global Research & Development